Triptorelin
- Generic Name
- Triptorelin
- Brand Names
- Decapeptyl, Trelstar, Triptodur
- Drug Type
- Small Molecule
- Chemical Formula
- C64H82N18O13
- CAS Number
- 57773-63-4
- Unique Ingredient Identifier
- 9081Y98W2V
- Background
Triptorelin is a synthetic decapeptide agonist analog of luteinizing hormone releasing hormone (LHRH). Possessing greater potency than endogenous LHRH, triptorelin reversibly represses gonadotropin secretion. After chronic, continuous administration, this agent effects sustained decreases in LH and FSH production and testicular and ovarian steroidogenesis. Serum testosterone concentrations may fall to levels typically observed in surgically castrated men.
- Indication
Triptorelin is indicated for the palliative treatment of advanced prostate cancer.
- Associated Conditions
- Advanced Prostate Cancer
- Associated Therapies
- Controlled ovarian hyperstimulation therapy
Endometrial Receptivity After GnRH Agonist Triggering
- Conditions
- Ovarian Hyperstimulation Syndrome
- Interventions
- First Posted Date
- 2011-12-29
- Last Posted Date
- 2016-10-26
- Lead Sponsor
- IVI Madrid
- Target Recruit Count
- 35
- Registration Number
- NCT01500863
- Locations
- 🇪🇸
Instituto Valenciano de Infertilidad, Madrid, Spain
Ovarian Stimulation Using Recombinant Follicle-stimulating Hormone (FSH) and Gonadotrophin Releasing Hormone (GnRH) Agonist in Alternate Days
- First Posted Date
- 2011-11-09
- Last Posted Date
- 2012-07-13
- Lead Sponsor
- Fertility - Assisted Fertilization Center
- Target Recruit Count
- 96
- Registration Number
- NCT01468441
- Locations
- 🇧🇷
Fertility - Assisted Fertilization Center, Sao Paulo, Brazil
Efficacy, Safety, and Pharmacokinetics (PK) of Triptorelin 6-month Formulation in Patients With Central Precocious Puberty
- First Posted Date
- 2011-11-09
- Last Posted Date
- 2017-07-28
- Lead Sponsor
- Debiopharm International SA
- Target Recruit Count
- 44
- Registration Number
- NCT01467882
- Locations
- 🇺🇸
Swedish Pediatric Specialist, Seattle, Washington, United States
🇨🇱IDIMI, Santiago, Chile
🇲🇽Hospital Universitario de Monterrey, Monterrey, Mexico
Efficiency of Gonadotropin-releasing Hormone (GnRH) Agonist in Preventing Chemotherapy Induced Ovarian Failure
- Conditions
- Alkylating AgentsLymphomaFertility Preservation
- Interventions
- First Posted Date
- 2010-07-12
- Last Posted Date
- 2015-10-30
- Lead Sponsor
- Erasme University Hospital
- Target Recruit Count
- 118
- Registration Number
- NCT01160315
- Locations
- 🇫🇷
Hôpital Hotel Dieu, Paris, France
🇧🇪AZ St Jan, Brugges, Belgium
🇧🇪CHRU Lille, Lille, Belgium
Single Dose Gonadotropin-releasing Hormone (GnRH) Agonist Administration in the Luteal Phase of GnRH Antagonist Stimulated ICSI-ET Cycles
- First Posted Date
- 2009-11-04
- Last Posted Date
- 2009-11-04
- Lead Sponsor
- V.K.V. American Hospital, Istanbul
- Registration Number
- NCT01007851
- Locations
- 🇹🇷
American Hospital, Istanbul, Turkey
A 4 Year Combination Therapy of Growth Hormone and (GnRH) Agonist in Children With a Short Predicted Height
- Conditions
- Idiopathic Short Stature
- Interventions
- First Posted Date
- 2009-02-11
- Last Posted Date
- 2023-07-28
- Lead Sponsor
- Belgian Study Group for Pediatric Endocrinology
- Target Recruit Count
- 44
- Registration Number
- NCT00840944
- Locations
- 🇧🇪
CHU ND-des Bruyères, Liege, Belgium
🇧🇪Antwerp University Hospital, Edegem, Antwerpen, Belgium
🇧🇪Kinderziekenhuis UZ Brussel, Brussel, Belgium
A Study to Assess the Efficacy and Safety of Ganirelix (Orgalutran®) Treatment in Chinese Women Undergoing Controlled Ovarian Stimulation for in Vitro Fertilization (IVF) or Intra Cytoplasmatic Sperm Injection (ICSI) (Study 38651)(P05703)
- Conditions
- Controlled Ovarian Stimulation
- Interventions
- First Posted Date
- 2008-07-30
- Last Posted Date
- 2022-02-03
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 259
- Registration Number
- NCT00725491
Pregnancy and Neonatal Follow-up of Ongoing Pregnancies Established in Clinical Trial 38833 (P05783)
- Conditions
- NeonatesPregnancy
- Interventions
- Drug: Corifollitropin alpha (MK-8962, Org 36286) 150 ugDrug: Corifollitropin alpha (MK-8962, Org 36286) 100 ugDrug: TriptorelinBiological: Recombinant follicle stimulating hormone (recFSH)Biological: Human chorionic gonadotprophin (hCG).
- First Posted Date
- 2008-06-20
- Last Posted Date
- 2022-02-03
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 15
- Registration Number
- NCT00702520
Triptorelin and Radiation Therapy in Treating Patients Who Have Undergone Surgery for Intermediate-Risk Stage III or Stage IV Prostate Cancer
- Conditions
- Prostate Cancer
- Interventions
- First Posted Date
- 2008-04-25
- Last Posted Date
- 2024-06-17
- Lead Sponsor
- UNICANCER
- Target Recruit Count
- 424
- Registration Number
- NCT00667069
- Locations
- 🇫🇷
Centre Hospitalier Universitaire Henri Mondor, Creteil, France
🇫🇷Clinique du Pont de Chaume, Montauban, France
🇫🇷Centre Henri Becquerel, Rouen, France
Brain Function in Premenopausal Women Receiving Tamoxifen With or Without Ovarian Function Suppression for Early-Stage Breast Cancer on Clinical Trial IBCSG 24-02
- Conditions
- FatigueBreast CancerSleep Disorders
- Interventions
- First Posted Date
- 2008-04-16
- Last Posted Date
- 2016-07-25
- Lead Sponsor
- ETOP IBCSG Partners Foundation
- Target Recruit Count
- 86
- Registration Number
- NCT00659373
- Locations
- 🇺🇸
Front Range Cancer Specialists, Fort Collins, Colorado, United States
🇺🇸New Hampshire Oncology - Hematology, PA at Payson Center for Cancer Care, Concord, New Hampshire, United States
🇺🇸Batte Cancer Center at Northeast Medical Center, Concord, North Carolina, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.